Similar articles for PMID: 28720101

Year	Number of Results
2002	1
2003	1
2004	2
2005	3
2006	1
2008	1
2009	4
2010	6
2011	4
2012	3
2013	4
2014	7
2015	2
2016	10
2017	6
2018	8
2019	5
2020	14
2021	6
2022	10
2023	8
2024	2

1

Drug candidates in clinical trials for Alzheimer's disease.

Hung SY, Fu WM. Hung SY, et al. J Biomed Sci. 2017 Jul 19;24(1):47. doi: 10.1186/s12929-017-0355-7. J Biomed Sci. 2017. PMID: 28720101 Free PMC article. Review.

2

Therapeutic strategies for Alzheimer's disease in clinical trials.

Godyń J, Jończyk J, Panek D, Malawska B. Godyń J, et al. Pharmacol Rep. 2016 Feb;68(1):127-38. doi: 10.1016/j.pharep.2015.07.006. Epub 2015 Aug 5. Pharmacol Rep. 2016. PMID: 26721364 Review.

3

Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.

Pinheiro L, Faustino C. Pinheiro L, et al. Curr Alzheimer Res. 2019;16(5):418-452. doi: 10.2174/1567205016666190321163438. Curr Alzheimer Res. 2019. PMID: 30907320 Review.

4

Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.

Dinda B, Dinda M, Kulsi G, Chakraborty A, Dinda S. Dinda B, et al. Eur J Med Chem. 2019 May 1;169:185-199. doi: 10.1016/j.ejmech.2019.03.009. Epub 2019 Mar 8. Eur J Med Chem. 2019. PMID: 30877973 Review.

5

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A. Panza F, et al. Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Immunotherapy. 2012. PMID: 22339463 Review.

6

Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.

Panza F, Seripa D, Solfrizzi V, Imbimbo BP, Lozupone M, Leo A, Sardone R, Gagliardi G, Lofano L, Creanza BC, Bisceglia P, Daniele A, Bellomo A, Greco A, Logroscino G. Panza F, et al. Expert Opin Emerg Drugs. 2016 Dec;21(4):377-391. doi: 10.1080/14728214.2016.1241232. Epub 2016 Oct 6. Expert Opin Emerg Drugs. 2016. PMID: 27678025 Review.

7

Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.

Mazumder MK, Choudhury S. Mazumder MK, et al. Med Hypotheses. 2019 Apr;125:94-99. doi: 10.1016/j.mehy.2019.02.035. Epub 2019 Feb 14. Med Hypotheses. 2019. PMID: 30902161

8

Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.

Imbimbo BP, Ippati S, Watling M, Imbimbo C. Imbimbo BP, et al. Pharmacol Res. 2023 Jan;187:106631. doi: 10.1016/j.phrs.2022.106631. Epub 2022 Dec 28. Pharmacol Res. 2023. PMID: 36586644 Free article. Review.

9

Disease-modifying therapies in Alzheimer's disease: how far have we come?

Hüll M, Berger M, Heneka M. Hüll M, et al. Drugs. 2006;66(16):2075-93. doi: 10.2165/00003495-200666160-00004. Drugs. 2006. PMID: 17112302 Review.

10

Passive immunotherapy for Alzheimer's disease.

Guo X, Yan L, Zhang D, Zhao Y. Guo X, et al. Ageing Res Rev. 2024 Feb;94:102192. doi: 10.1016/j.arr.2024.102192. Epub 2024 Jan 14. Ageing Res Rev. 2024. PMID: 38219962 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year